Evidence map›Paper›PMID 32291416›Full record

ArticleNature medicine2020

Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.

Jennifer N Brudno, Norris Lam, Danielle Vanasse, Yueh-Wei Shen, Jeremy J Rose, John Rossi, Allen Xue, Adrian Bot, Nathalie Scholler, Lekha Mikkilineni and 10 more

Registry-linked trialAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06590545 (Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06590545 phase1 / phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis: a Two-stage Interventional, Prospective, Open-label, Phase I/II Trial in Patients With Active, Treatment Refractory, ANCA-IgG-positive Vasculitis

TypeinterventionalSponsorDavid SimonRan2025 to 2027Enrolled8ConditionsANCA-IgG-positive ANCA Associated VasculitisArmsKYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Jennifer N BrudnoExperimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
Norris LamExperimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
Danielle VanasseExperimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
Yueh-Wei ShenKite Pharma, Santa Monica, CA, USA.
Jeremy J RoseExperimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
John RossiKite Pharma, Santa Monica, CA, USA.
Allen XueKite Pharma, Santa Monica, CA, USA.
Adrian BotKite Pharma, Santa Monica, CA, USA.
Nathalie SchollerKite Pharma, Santa Monica, CA, USA.ORCID http://orcid.org/0000-0003-3743-7102
Lekha MikkilineniMedical Oncology/Hematology Fellowship Program, NCI, Bethesda, MD, USA.
Mark RoschewskiLymphoid Malignancy Branch, Center for Cancer Research, NCI, NIH Bethesda, Bethesda, MD, USA.
Robert DeanCleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.
Raul CachauAdvanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0001-9260-2102
Philippe YoukharibacheCancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Rashmika PatelOffice of Regulatory Affairs, NCI, NIH, Bethesda, MD, USA.
Brenna HansenExperimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
David F StroncekCenter for Cellular Engineering, Clinical Center, NIH, Bethesda, MD, USA.
Steven A RosenbergSurgery Branch, Center for Cancer Research, NCI, NIH Bethesda, Bethesda, MD, USA.
Ronald E GressExperimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
James N KochenderferExperimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA. kochendj@mail.nih.gov.ORCID http://orcid.org/0000-0002-4362-9875

Funding

Gene therapy of cancerZIABC010985 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROSENBERG, STEVEN · 2009 to 2025
$56.8M
ETIB Clinical Research CoreZIDBC010963 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GRESS, RONALD · 2009 to 2023
$28.6M
Building on the success of the adoptive immunotherapy of cancerZIABC010763 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROSENBERG, STEVEN · 2009 to 2020
$25.0M
New Chimeric Antigen Receptors for Treating Hematologic MalignanciesZIABC011417 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOCHENDERFER, JAMES · 2011 to 2025
$8.3M
Adoptive Cell Transfer Immunotherapy of CancerZ01BC010984 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROSENBERG, STEVEN · 2008 to 2008
$1.5M
Intramural NIH HHS Z01 BC010984
6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID32291416
PMCPMC7819238

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.